PRLD PEER ANALYSIS

Prelude Therapeutics Inc — metric-by-metric comparison with peers and the industry median

PRLDPrelude Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

PRLDIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	PRLD	MSB	TLX	RTALB	Ind. Median
P/E	—	—	—	4.89	17.91
P/B	6.73	—	6.37	0.61●	3.51
EV/EBITDA	—	—	120.14	74.61●	14.82
P/S	24.23	31.61	3.24●	6.67	10.89

Financial Health
Metric	PRLD	MSB	TLX	RTALB	Ind. Median
Current Ratio	2.03●	—	1.43	1.21	5.90
Debt/Equity	29.4%	—	112.3%	1.2%●	10.9%
NetDebt/EBITDA	0.84●	—	13.13	0.90	1.15

Profitability
Metric	PRLD	MSB	TLX	RTALB	Ind. Median
Net Margin	-465.3%	-115.3%	-0.9%	136.3%●	-125.7%
ROE	-95.2%	-11.3%	-1.8%	15.1%●	-47.5%
ROA	-59.6%	-8.6%	-0.7%	13.1%●	-35.8%
EBITDA Margin	-455.3%	-76.6%	3.0%	9.0%●	-105.8%

Growth + Dividend
Metric	PRLD	MSB	TLX	RTALB	Ind. Median
Rev. Growth	138.9%	410.4%●	56.3%	24.0%	5.1%
NI Growth	—	—	—	134.0%	12.1%
Div. Yield	—	0.0%●	—	0.0%●	0.2%
Payout	—	0.0%	—	0.0%	0.0%

Valuation
Metric	PRLD	AVIR	ALT	CMPX	KROS	APLS	Ind. Median
P/E	—	—	—	—	—	3.22	17.91
P/B	6.73	1.69	1.38	2.27	1.49	1.03●	3.51
EV/EBITDA	—	—	—	—	—	2.77	14.82
P/S	24.23	—	10,924.98	—	12.85	0.39●	10.89

Financial Health
Metric	PRLD	AVIR	ALT	CMPX	KROS	APLS	Ind. Median
Current Ratio	2.03	7.89	29.56●	19.04	22.62	3.63	5.90
Debt/Equity	29.4%	0.3%●	12.6%	5.3%	5.7%	114.7%	10.9%
NetDebt/EBITDA	0.84	1.42	3.35	2.76	2.99	0.38●	1.15

Profitability
Metric	PRLD	AVIR	ALT	CMPX	KROS	APLS	Ind. Median
Net Margin	-465.3%	—	-253,002.8%	—	-256.6%	12.1%●	-125.7%
ROE	-95.2%	-52.6%	-42.7%	-45.9%	-16.8%	46.0%●	-47.5%
ROA	-59.6%	-48.0%	-37.0%	-40.5%	-15.5%	14.1%●	-35.8%
EBITDA Margin	-455.3%	—	-245,200.0%	—	-267.4%	16.3%●	-105.8%

Growth + Dividend
Metric	PRLD	AVIR	ALT	CMPX	KROS	APLS	Ind. Median
Rev. Growth	138.9%●	-100.0%	80.0%	-100.0%	-84.5%	42.5%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on PRLD

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.